2 results
Approved WMOPending
The objectives of this are to establish the safety, tolerability, and preliminary efficacy of VRDN-001, and the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of VRDN-001 in NHV and TED patients over a dose range of 3.0 to 20.0 mg/kg.
Approved WMOPending
This research aims to examine the feasibility of home monitoring of serum uric acid for both patients and stakeholders, using a digital home measuring device in conjunction with a nurse-led T2T approach.Primary research question:What is theā¦